🚀 Your digital skills journey starts here! Join us for Learn Basic Tech, a free virtual training that makes learning technology approachable and accessible.
When: Fri, Nov 13, 9 am
RSVP: https://t.co/n5oJKt6OcS
That's a serious resume, not your usual meme-coin CEO. Waterloo CS plus BlackBerry-era mobile and global MRP systems is real pedigree
#BBNaija
$SMCI $OKLO
For $HIMS followers, I found a different healthcare angle: $NXXT signed a 25-year Taft Medical energy deal with 320 kW of solar, 240 kWh of storage and 6 EV chargers. About $3.5M in contracted payments. Can this model scale?
$NXXT $HIMS $CRWV #Energy
$end
Prior data with actual dose-ranging is a way better starting point than most deals get. Changes the risk profile for sure.
#WednesdayMotivation
$QUBT $NVDA
I dug into NitroMist's original evidence: a 30-patient trial tested 200, 400 and 800 mcg sprays against placebo. That was years before $VICP's proposed $2M deal. For $SLS followers, does prior clinical evidence change the risk?
$VICP $QQQ $SLS #Biotech
$VICP's Google Finance snapshot showed a $0.10–$1.50 52-week range and roughly 32.37M shares outstanding. A 15x range isn't a return anyone necessarily earned. For $RKLB traders, how much does OTC liquidity matter?
$VICP $QQQ $RKLB #Stocks
Here's a number I rarely see in $VICP posts: volume fell from 5,100 shares on Nov 2 to 1,400 on Nov 4, while both sessions closed at $0.50. For $CAPR traders, is the liquidity story as important as the science?
$VICP $MU $CAPR #OTCStocks
A small study made me stop scrolling: a 2025 CXCL12 paper tied to $VICP followed just 2 primates, with C-peptide detected for 13 weeks in the diabetic animal. It's not human efficacy. For $CAPR traders, what comes next?
$VICP $MU $CAPR #Biotech